The investment will help expand the accessibility of Eko’s early detection platform across key global markets.

Summary: Eko Health, an AI developer for early detection of heart and lung diseases, has raised $41 million in Series D financing to expand its early disease detection platform in the US and internationally. The platform, used by over 500,000 healthcare professionals, combines FDA-cleared algorithms with digital medical devices to enhance detection during physical exams. Recent milestones include FDA clearances for detection algorithms and clinical validations demonstrating improved identification rates of heart conditions.

Key Takeaways:

  • Eko Health has secured $41 million to enhance the accessibility of its AI-based early detection platform for heart and lung diseases globally.
  • The platform’s algorithms have received FDA clearances and demonstrated improved detection rates in clinical studies.
  • Eko’s platform, which combines digital devices with AI, is used by over 500,000 healthcare professionals, aiming to reduce diagnostic bottlenecks and improve patient outcomes through earlier interventions.

Eko Health, a developer of artificial intelligence (AI) solutions for early detection of heart and lung diseases, has raised $41 million in Series D financing to expand US and global access to the company’s early disease detection platform.

Eko, used by over 500,000 healthcare professionals worldwide, combines US Food and Drug Administration (FDA)-cleared algorithms with digital medical devices to enhance the early detection of cardiac and pulmonary diseases during physical exams.

The funding builds on recent commercial and clinical milestones, including US FDA clearances for its structural heart murmur and low ejection fraction (Low EF) detection algorithms. Eko’s murmur detection algorithm was clinically validated in a Massachusetts General Hospital study and found to double identification rates of structural heart murmurs versus conventional practice in primary care. 

The low EF detection algorithm, developed with Mayo Clinic, was shown in an Imperial College London study to significantly enhance the identification of heart failure with reduced ejection fraction in GP clinics. By enhancing detection capabilities, Eko’s platform significantly reduces diagnostic bottlenecks, leading to earlier interventions and improved patient outcomes.

“Eko harnesses AI to unlock universal access to expert-level cardiac and pulmonary disease detection for patients everywhere,” says Connor Landgraf, CEO and co-founder of Eko Health, in a release. “Just as Ring transformed doorbells into home security systems, Eko has reinvented the world’s most ubiquitous medical tool into a powerful early disease detection platform, creating the world’s largest install base of professional AI-enabled cardiology devices.”

Eko will use the new capital to deepen its presence in the US and accelerate its expansion into key international markets. 

“Eko has spent the past decade building an unparalleled dataset of digital heart and lung sounds, which it leverages to develop clinical AI for the physical world,” says Vas Bailey, PhD, Chair of the Board at Eko Health and Partner at ARTIS Ventures, which supported the funding round. “Like countless others, I lost a parent much too early to undetected heart disease. I am deeply inspired by the team’s dedication to saving lives by equipping hundreds of thousands—and soon millions—of clinicians worldwide with our groundbreaking early detection platform.”

Photo caption: Eko

Photo credit: Eko Health